Vectura Group (VEC)

 

VEC Share PerformanceMore

52 week high200.10 12/01/16
52 week low122.90 30/08/16
52 week change -36.70 (-21.03%)
4 week volume38,063,958 12/11/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Vectura updates on Ultibro Breezhaler

Vectura Group confirms the announcement by Novartis of positive results from the first large-scale study exploring the e...

Ultibro Breezhaler improved lung function

RNS Number: 2560R Vectura Group plc 08 December 2016 Ultibro Breezhaler improved lung function and COPD symptoms after direct switch from previous treatment Ultibro Breezhaler improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the 2017 GO...

Total Voting Rights

RNS Number: 6321Q Vectura Group plc 01 December 2016 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 1 December 2016: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following: T...

Investors unfazed by Autumn Statement

The blue chip index was flat following the Autumn Statement as investors were unimpressed by the UK government's pla...

Estate agents hammered on letting fees speculation

The FTSE 100 rallied 0.3% to 6,840 after from a positive session on Wall Street overnight and ahead of the Autumn Stateme...

Vectura materially widens H1 pretax loss

Vectura has materially widened its H1 pretax loss to 22.4m, from a loss of 5m. Revenue was much lower at 73.9m, from 26...

Interim Results

RNS Number: 8903P Vectura Group plc 23 November 2016 Vectura Group plc Interim Results Step-change in financial performance and uniquely positioned for future growth Strengthened pipeline includes seven late stage assets Chippenham, UK - 23 November 2016: Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading device and formulation business...

Further Collaboration with Hikma

RNS Number: 7654P Vectura Group plc 22 November 2016 Vectura Group plc Vectura announces a further collaboration with Hikma for the development of generic salmeterol for the US (VR730) Chippenham, UK - 22 November 2016: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading inhaled airways disease focused business, today ann...

Fundamental DataMore

P/E ratio114.833
EPS1.2
Dividend yield0 %

Latest discussion posts More

  • Re: Good News

    I suspect that Investegate will be the first website you visit after 7.00 am every day - in 3 mins you can scroll down every RNS published
    8-Dec-2016
    dave297
  • Re: Good News

    Thanks Dave I will investigate 'Investegate'. iii seems to be getting worse and worse for trying to keep abreast of investments, the news tickers come up but then it takes ...
    8-Dec-2016
    dkok
  • Re: Good News

    Sorry Dkok & thanks to Ambi for providing the full RNS.I look at the 7am Stock Exchange RNS announcements every morning, via" investegate", to see if any of the companies I am ...
    8-Dec-2016
    dave297

Users' HoldingsMore

Users who hold Vectura Group also hold..
LLOYDS GRP.27%
VODAFONE GRP.22%
BP19%
BARCLAYS16%
TESCO16%

Codes & Symbols

ISINGB00B01D1K48
SymbolsVEC, LSE:VEC, VEC.L, VEC:LN, LON:VEC, XLON:VEC